In total, 73 479 participants from these trials were included in this meta-analysis.59 In the CETP inhibitor group, 960 patients developed new-onset diabetes compared with 1086 patients in the placebo group, a 12% reduction in diabetes risk (OR: 0.88, 95% CI: 0.81–0.96; P = 0.005). This evidence concerns the gene CETP and diabetes mellitus.